<DOC>
	<DOCNO>NCT00000572</DOCNO>
	<brief_summary>To compare conventional therapy use low frequency positive pressure ventilation extracorporeal CO2 removal treatment adult respiratory distress syndrome ( ARDS ) .</brief_summary>
	<brief_title>Extracorporeal Carbon Dioxide Removal Acute Respiratory Distress Syndrome</brief_title>
	<detailed_description>BACKGROUND : It estimate least 150,000 individual die year adult respiratory distress syndrome . Treatment remain largely supportive . The National Heart , Lung , Blood Institute ( NHLBI ) conduct Extracorporeal Support Respiratory Insufficiency ( ECMO , Extracorporeal Membrane Oxygenation ) trial June 1974 1978 . In ECMO , 90 patient randomize either extracorporeal membrane oxygenation plus conventional therapy conventional therapy . Survival rate less ten percent group . The failure trial demonstrate superiority ECMO conventional ventilatory support result virtual elimination use ECMO clinical medicine . In early NHLBI trial , ECMO implement veno-arterial shunt approximate 90 percent baseline cardiac output . Ventilation lung continue reduced function inspiration oxygen . Thus , lung deprive principle source blood supply continuously expose potentially injurious ventilatory pressure gas composition . The present patient trial use new form therapy develop Dr. Gattinoni co-worker Milan , Italy collaboration Dr. Kolobow National Institutes Health Bethesda . The author report 77 percent survival rate new therapy . In Step 1 new therapy , patient initially ventilate pressure-controlled , inverted ratio ventilation . If patient improve , Step 2 use extracorporeal perfusion perform veno-venous shunt contrast veno-arterial shunt . The veno-venous shunt preserve pulmonary blood flow whereas veno-arterial shunt diminish . Step 3 reserved patient meet therapeutic criterion Step 2 . They undergo low frequency positive-pressure ventilation extracorporeal CO2 removal involve veno-venous bypass via internal jugular femoral bilateral saphenous vein . DESIGN NARRATIVE : Randomized , fixed sample . Patients stratified age ( 40 year ) presence absence trauma . Patients assign conventional positive pressure ventilation therapy three-step therapeutic program employ pressure-controlled-inverted-ratio-ventilation , continuous positive airway pressure , low-frequency positive pressure ventilation-extracorporeal CO2 removal . The main outcome measure survival 30 day randomization . Secondary outcome measure include hospital cost , physiologic data , length hospital stay , blood product consumption . Follow-up take place year hospital discharge .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>Men woman acute respiratory distress syndrome . ECMO ENTRY CRITERIA ( PaO2 &lt; 50 mm Hg REPEATED THREE TIMES ) : Rapid entry : 2 hour fraFIO2=1.00 PEEP &gt; 5 cm H2O PaCO2=3045 mmHg Slow entry : 12 hour fraction inspire oxygen ( FIO2 ) &gt; 0.60 positive endexpiratory pressure ( PEEP ) &gt; 5 cm H2O PaCO2=3045 mmHg right Left shunt fraction &gt; 0.30 1 . Contraindication anticoagulation ( example , gastrointestinal bleeding , recent cerebrovascular accident , chronic bleed disorder ) . 2 . Pw &gt; 25 mm Hg ( supersede screen criterion Pw ~ 15 mm Hg ) . 3 . Mechanical ventilation &gt; 21 . day . 4 . Severe chronic systemic disease another clinical condition , , greatly limit survival ; example , 1 . Irreversible central nervous system disease 2 . Severe chronic pulmonary disease ( forced expiratory volume 1 second ( FEV1 ) &lt; 1 L , FEV1/FVC ( force vital capacity ) &lt; 0.3 predict , chronic PaCO2 &gt; 45 mm Hg , chest xray evidence overinflation interstitial infiltration , previous hospitalization chronic respiratory insufficiency ) 3 . Totalbody surface burn &gt; 40 % 4 . Rapidly fatal malignancy 5 . Chronic leave ventricular failure 6 . Chronic renal failure ( require serum creatlnlne ~ 2 mg/dl chronic dialysis therapy ) 7 . Chronic liver failure ( require total serum bilirubin ; ? ; 2 mg/dl ) 8 . Immunosuppressed patient patient positive human immu.. nodeficiency virus test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>